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Introduction
Radioactive iodine (RAI) therapy is one of the mainstays for 
managing patients with differentiated thyroid carcinoma 
(DTC) and has a definitive role in selected cases with 
distant metastases (1). However, the effectiveness of ablative 
or adjuvant RAI therapy for preventing oncologic events 
in surgically curable diseases has been controversial (2-4), 
and it has not been widely used in Japan (5-7). For example, 
only 1.5% of patients received RAI therapy for papillary 
thyroid carcinoma (PTC) in our department between 1981 
and 1991, even though 35% of the cohort were deemed to 
have high-risk PTC (8). As Higashi et al. described, there 
are several reasons for this, including “radiophobia” among 
Japanese individuals, surgeons’ belief in the effectiveness of 
less than total thyroidectomy (i.e., subtotal thyroidectomy 
or lobectomy) which precluded use of RAI, and limited 
availability of facilities for RAI therapy (7). 
Availability of RAI therapy
In Japan, RAI therapy has not been readily provided in 
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a timely manner to patients in need (6,7). Successive 
nationwide surveys on the status quo of RAI therapy for 
DTC in Japan have revealed that the number of beds 
dedicated to inpatient care has decreased. In contrast, the 
number of inpatient cases treated with RAI for adjuvant 
or therapeutic purposes has increased to nearly 3,000 
during the past two decades (Figure 1) (9-14). There are 
two reasons for the decline in available beds (5-7). First, 
the Ministry of Health, Labour and Welfare of Japan has 
established fairly stringent and comprehensive regulations 
on the use of radioactive materials and release of patients 
following RAI therapy. Medical institutions have been 
spending a considerable amount to equip and maintain 
exclusive facilities, such as shield rooms, local air exhausters, 
filters, drainage, and waste disposal tanks, to observe the 
rules. However, the second reason is that the Japanese 
health insurance system does not fully reimburse the actual 
expenses. More than 90% of respondents in the nationwide 
survey felt that coverage was insufficient (12). Therefore, 
several hospitals had to abandon RAI therapy because of the 
financial load (7).
Another problem is that patients with recurrent disease 
have to wait for a long time to receive RAI therapy. Although 
the average waiting time decreased from 5.2 months 
in 2010 to 3.8 months in 2018, there is still room for 
improvement (Figure 2) (9-13). In fact, the distribution 
and availability of medical facilities vary across the country, 
and some patients have to wait for >9 months to receive 
treatment for their metastatic lesions (13). This observation 
posed serious concerns on the potential effects of such a 
long waiting period on the oncologic outcomes. Higashi 
et al. reported that delayed RAI therapy for metastatic 
DTC was significantly associated with poor disease-specific 
survival, and the hazard ratio of the interval from surgery to 
initial RAI therapy ≥180 days compared to that of <180 days 
was 4.22 (95% CI, 1.55–11.5) (15).
To overcome the potential harm caused by the shortage 
of dedicated facilities, Japanese experts initiated thyroid 
remnant ablation for DTC with a dose of 1,110 MBq of 
RAI in an outpatient clinic, following a pivotal study that 
examined the safety of the procedure. Kusakabe et al. of 
the Japanese Society of Nuclear Medicine concluded that 
outpatient-based ablation with 1,110 MBq of RAI after total 
thyroidectomy in patients with DTC was safe if applied 
under appropriate supervision and guidance by experts with 
specific qualifications (16). The number of patients treated 
with ablative RAI therapy in an outpatient basis increased 
from 764 in 2012 to 1,642 in 2017, according to the surveys 
(Figure 1) (14). In contrast, the number of inpatient cases 
remained at the same level, and the waiting time did not 
show a significant change (Figures 1,2). The need for RAI 
therapy for metastatic lesions can be expected to increase 
Figure 1 Time trends of the numbers of available beds, outpatient cases, and inpatient cases of RAI therapy for thyroid cancer. 
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because patients with PTC with high-risk features have 
sustained hazard of developing recurrence, even ≥10 years 
after initial treatment (8). Moreover, it is recommended that 
RAI therapy be performed first for unresectable progressive 
DTC, and molecular-targeted drugs are indicated only 
when the lesions are refractory to the treatment.
Clinical practice guidelines for thyroid cancer
Following the initial development of the clinical practice 
guidelines for thyroid tumors in 2010 (17-19), the Japan 
Association of Endocrine Surgeons (JAES) and the 
Japanese Society of Thyroid Surgeons (JSTS) revised the 
guidelines in 2018 (20,21). The guidelines set four risk 
categories as an initial assessment of PTC based on the 
pre- or intraoperative findings according to the UICC 
TNM classification (22): very low-risk PTC measuring 
≤1 cm without any metastases (T1aN0M0); low-risk PTC 
measuring 1.1–2 cm without any metastases (T1bN0M0); 
high-risk PTC having at least one of the features including 
tumor size >4 cm, extrathyroidal extension or extranodal 
extension to adjacent structures except for the sternothyroid 
muscle, clinical node metastasis >3 cm, and M1; and 
intermediate-risk PTC, which indicates a tumor that does 
not meet any of the definitions for the very low-, low-, or 
high-risk categories (17-21). The guidelines are unique in 
that the management strategies are recommended according 
to the risk categories (Figure 3). Active surveillance without 
surgery can be an option for patients with very low-risk 
PTC, while lobectomy, along with prophylactic central node 
dissection, is a treatment of choice for very low- and low-
risk PTC. Total thyroidectomy plus appropriate central/
lateral lymph node dissection followed by RAI therapy and 
thyrotropin suppression therapy is recommended for high-
risk PTC. For intermediate-risk PTC, sound judgment 
is required to determine the extent of thyroidectomy 
and lymph node dissection by considering each patient’s 
characteristics and prognostic factors.
Considering the poor prognosis associated with high-
risk PTC (8), Japanese experts reached a consensus that 
employing all available treatments would be necessary 
to reduce oncologic events. This recommendation must 
have been reflected in the rise of ablative RAI therapy 
on an outpatient basis during the past decade (Figure 1). 
However, so far, there is no substantial evidence to support 
the advantages of total thyroidectomy, ablative RAI therapy, 
and thyrotropin suppression therapy (21).
RAI therapy: definitions, goals, and evidence
The Japanese guidelines classify RAI therapy into three 
categories in line with those set by the latest guidelines 
developed by the American Thyroid Association (ATA) in 
2015: ablation, adjuvant therapy, and treatment (Figure 4) (23). 
Figure 3 Flowchart of the initial management of PTC (the revised Japanese clinical practice guidelines for thyroid tumors) (20,21). PTC, 
papillary thyroid carcinoma; ETE, extrathyroidal extension; ENE, extranodal extension; D1, lymph node dissection of the central neck area; 
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Ablation aims to eliminate remnant normal follicular cells 
to facilitate the detection of recurrence by measuring 
thyroglobulin (Tg) levels. Adjuvant therapy is expected to 
improve recurrence-free and disease-specific survival by 
destroying microscopic residual cancer cells. RAI treatment 
is a therapy for a persistent disease that is not suitable for 
surgical therapy. Although the recommended dose of RAI 
for adjuvant therapy is 3,700–5,600 MBq (100–150 mCi), 
it is not attainable in Japan because the dedicated resources 
have been quite limited, as described above. Some patients 
who are candidates for adjuvant RAI therapy have been 
treated with 1,110 MBq (30 mCi) of RAI under “ablation.”
Ablation
Recently, researchers from three institutions in Japan 
reported the efficacy of ablation using RAI 1,110 MBq 
(Figure 5) (24-26). Ablation success was achieved in 53% 
(95% CI, 38–68%) at Gunma University, 74% (95% CI, 
61–83%) at Kyoto University, and 23% (95% CI, 15–33%) 
at Tokyo Women’s Medical University. Several factors may 
explain the observed differences. The criteria in assessing a 
diagnostic whole-body scan (DxWBS) and the definitions 
of ablation success were different among the three reports. 
Particularly, Abe et al. used the most stringent definition 
for ablation success comprising of negative DxWBS and 
stimulated Tg level <2 ng/mL compared to that used by the 
other two studies (26). Study populations were also different 
in terms of the risk class of PTC. The proportion of 
patients with high-risk PTC was 23% at Gunma University, 
34% at Kyoto University, and 45% at Tokyo Women’s 
Medical University, whereas that of patients with low-risk 
PTC was 13%, 0%, and 0%, respectively. Furthermore, the 
investigators from Gunma and Kyoto University classified 
patients according to the ATA 2015 guidelines, while the 
authors at the Tokyo Women’s Medical University referred 
to the Japanese 2018 guidelines. The two guidelines differ 
in some respects in defining the risk class for PTC (Figure 6). 
The Japanese classification is based on the pre- and 
intraoperative assessment, while the ATA classification 
uses pathological evaluation. For example, T3a (>4 cm) 
PTC without lymph node metastasis would be classified 
as high-risk based on the Japanese guidelines, but it would 
be classified as low-risk based on the ATA guidelines. 
In contrast, T1b PTC with more than five microscopic 
lymph node metastases would still be classified as low-risk 
in Japan, but it would be classified as intermediate-risk in 
the United States. Nonetheless, all three studies observed 
that the serum Tg level, either pretreatment or at the time 
of treatment, is associated with the success or failure of 
ablation (24-26).
Adjuvant therapy
Finding relevant studies showing evidence of effectiveness, 
harms, and patients’ views were vital in formulating 
recommendations for RAI adjuvant therapy during 
the revision of the Japanese guidelines. However, the 
development encountered a few difficulties as follows 
(20,21): first, some studies included both PTC and FTC 
under the name “differentiated thyroid carcinoma (DTC)” 
in the study population. Moreover, the definitions of risk 
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Figure 5 Efficacy of ablation using 1,110 MBq in Japan. TgAb, anti-thyroglobulin antibody; PTC, papillary thyroid carcinoma; ATA, 
American Thyroid Association; JPN, Japanese; NA, not available; DxWBS, diagnostic whole-body scan; Tg, thyroglobulin. 
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Figure 7 Ablative or adjuvant RAI therapy for PTC (the revised Japanese clinical practice guidelines for thyroid tumors) (20,21). PTC, 
papillary thyroid carcinoma.
class varied among studies and were different from those 
in the revised Japanese guidelines. Second, the distinction 
between “ablation”, “adjuvant”, and “treatment” was not 
always made accordingly, even in the relevant literature. 
Finally, there was a wide variation in the RAI doses among 
the studies.
Figure 7 summarizes the recommendations and evidence 
of ablative or adjuvant therapy for PTC presented in the 
Japanese 2018 guidelines (20,21). The optimal extent 
of thyroidectomy for low-risk PTC is lobectomy. Thus, 
RAI ablation is not recommended. There were no reports 
in which the study population fit the classification of 
intermediate-risk PTC defined by the Japanese 2018 
guidelines. Ruel et al. demonstrated the association between 
RAI administration and all-cause mortality in 21,870 cases 
of intermediate-risk PTC (pT3N0cM0-x, pT1-3N1cM0-x) 
registered in the National Cancer Database in the United 
States (27). The hazard ratio of adding RAI therapy was 
0.71 (95% CI, 0.62–0.82) for the entire population and 0.64 
(95% CI, 0.45–0.92) for patients aged <45 years. However, 
the absolute risk differences were quite small [1.9% (95% 
CI, 1.2–2.6%) for the entire population and 0.6% (95% 
CI, 0.1–1.1%)] for patients aged <45 years). Jonklaas et al. 
defined Stages III or IV DTC as high-risk disease and 
reported that adjuvant RAI therapy was associated with 
improved survival. The estimated risk ratios were 0.74 
(95% CI, 0.63–0.91) for all-cause mortality, 0.68 (95% CI, 
0.53–0.88) for carcinoma death, and 0.76 (95% CI, 0.60–
0.68) for carcinoma recurrence (28). The literature does not 
demonstrate that the use of adjuvant RAI therapy is effective 
in preventing oncologic outcomes in patients with high-risk 
PTC defined by the Japanese 2018 guidelines. Therefore, 
the quality of evidence supporting each recommendation 
was marked with representing poor evidence (20,21).














Post-operative adjuvant RAI therapy is recommended for
high-risk PTC without distant metastasis (M0)
• High-risk PTC: Use of RAI for Stage III or IV patients with DTC was associated with risk ratios of 0.74 
for all-cause mortality, 0.68 for cancer death, and 0.76 for cancer recurrence.
• Intermediate-risk PTC: RAI administration was associated with a better overall survival with 
hazard ratio of 0.71 for the entire population and 0.64 for patients <45 years-old, respectively, with 
T3N0M0-x or T1-3N1M0-x PTC.
• Low-risk PTC: RAI therapy has not been demonstrated to be effective in suppressing low risks of 
recurrence or death.
• Acute side effects, gastrointestinal symptoms, and radiation sialadenitis occurred in 60-70% of 
patients. Temporary effects on gonadal function and bone marrow may occur. Therapy-induced 
carcinoma may occur with an increase in dose, but the incidence is very low.
• Patients reported that “diagnosis of thyroid carcinoma is a life-changing event,” “it is not easy to 
determine to undergo RAI therapy,” and “experienced various symptoms after RAI therapy.”
Post-operative ablative RAI therapy is considered for
intermediate-risk PTC after due consideration of the
prognostic factors of each patient
Post-operative ablative RAI therapy is not recommended for
low-risk PTC
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Figure 8 RAI treatment for recurrent PTC (the revised Japanese clinical practice guidelines for thyroid tumors) (20,21). PTC, papillary 
thyroid carcinoma.
Treatment
RAI therapy is strongly recommended for lung or bone 
metastasis, while it is weakly recommended either local 
recurrence or lymph node metastasis that is inoperable 
for some reason but requires therapy. Although the 
Japanese 2018 guidelines cited some numerical data from 
the literature regarding the effectiveness of the treatment 
(Figure 8), the validity of such estimates is unsatisfactory 
because of the retrospective nature of their designs, limited 
number of subjects, and concomitant interventions that 
made patients’ clinical courses complex (20,21).
Dynamic evaluations and decisions
The definitions of RAI ablative or adjuvant therapy 
are apparent. However, clinical judgments may change 
according to the findings of imaging studies and serum Tg 
levels (Figure 9). When a patient is found to have residual 
accumulations outside the thyroid beds on the whole-
body scan following RAI administration and the lesions are 
confirmed by other imaging modalities, the individual must 
have treatments with either RAI ≥3,700 MBq or salvage 
surgery. In contrast, if the scan shows I-131 accumulation 
in the thyroid bed alone, then a decision will be made based 
on a follow-up diagnostic scan (DxWBS) and serum Tg 
level at 6–12 months. A patient has no residual disease when 
the DxWBS shows no accumulation of RAI and stimulated 
Tg level <2 ng/mL. In patients with uncertain responses 
defined by either a positive DxWBS scan at the thyroid bed 
or stimulated Tg level ≥2 ng/mL, a second administration 
of RAI ≥1,110 MBq needs to be considered.
Future directions
While RAI treatment is  a  crucial  e lement in the 
management of differentiated thyroid carcinoma throughout 











RAI therapy is strongly recommended for lung metastasis.
RAI therapy is strongly recommended for bone metastasis.
RAI therapy is weakly recommended for either local recurrence or lymph 
node metastasis that is inoperable but requires therapy.






• The response rate for lung metastasis showing iodine accumulation has been estimated to be 17% 
for complete response (CR), 44% for partial response (PR), 33% for stable disease (SD), and 6% for 
progressive disease (PD).
• 5-year, 10-year, and 15-year survival rates of cases with lung metastasis showing iodine accumulation 
have been estimated at 87%, 69%, and 56%, respectively.
• 5-year, 10-year, and 15-year survival rates of cases with lung metastasis without iodine accumulation 
have been estimated at 70%, 38%, and 21%, respectively.
• The rate of CR for bone metastasis was 50% in 8 cases aged 45 years or younger, and 21% for 99 
cases older than 45 years.
• The incidence of blood system disorders was reported as 37%.
• No reports have inquired about the patients’ perspective.
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Figure 9 Dynamic evaluations and decisions on ablative or adjuvant RAI therapy. WBS, whole-body scan; R0, curative resection; +ve, positive; 
-ve, negative; DxWBS, diagnostic whole-body scan; CT, computed tomography; US, ultrasonography; Tg, serum thyroglobulin level. 
the world, its use in Japan has been unique as compared to 
that in other countries due to various reasons. Now thanks 
to an evidence-based approach, we recognize no apparent 
differences in the recommendations for RAI use between in 
our latest guidelines and those in western ones (23). 
The objective of the JAES 2018 guidelines is to improve 
health-related outcomes in patients with thyroid tumors 
by minimizing gaps in knowledge among physicians. 
However, further clinical research is needed to make 
shared decision more evidence based. It is vital to conduct 
studies to examine the long-term outcomes of patients 
with intermediate- or high-risk PTC in Japan, yet such 
reports have never been published. The ablation success 
rate can be an alternative measure to determine the efficacy 
of RAI therapy using 1,110 MBq. Abe et al. concluded that 
low-dose RAI therapy might be inadequate in achieving 
successful ablation based on their observations (26). To this 
end, we are still facing the barrier to provide RAI therapy to 
patients as appropriate. Japanese experts in nuclear medicine 
have been making efforts to obtain approval for high-dose 
RAI administration on an outpatient basis to overcome 
the limited availability of resources for therapy (29). 
All relevant health professionals need to work closely in 
practice and research to ameliorate the current situation to 
care for patients with thyroid cancer.
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